Bemnifosbuvir is an investigational drug under development, primarily investigated for the treatment of hepatitis C virus (HCV) infection. It belongs to the class of NS5B polymerase inhibitors, which work by inhibiting viral replication, thereby aiding in the control and management of the infection.